Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

• Status: Recruiting
• Trial end date: 2030-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sherief Abd-Elsalam
• Treatments: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Alendronate

Criteria

Inclusion Criteria:

• • Male & female osteoporotic patient aged ≥ 50 years

• Hypertensive & normotensive patients

• BMD T-score ≥ 2.5 or more SD below peak bone mass

Exclusion Criteria:

• Patients on drugs that may improve osteoporosis disease state such as:

• Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.

Patients on drugs that may worsen osteoporosis disease state such as:

• Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.